Ninth Circuit Opens Door to FCA Liability for 340B Overcharges — New Legal Pathway for FQHCs
The Ninth Circuit unanimously reversed a dismissal in United States ex rel. Adventist Health System v. AbbVie, ruling that qui tam False Claims Act suits can proceed against pharmaceutical manufacturers that allegedly overcharge 340B covered entities above the statutory ceiling price. This creates a new private enforcement mechanism — previously only HRSA could enforce 340B ceiling price compliance. FQHCs can now pursue treble damages against manufacturers overcharging on 340B drugs.
Primary source
Sidley Austin LLPFQHC Talent. (2026, March 17). Ninth Circuit Opens Door to FCA Liability for 340B Overcharges — New Legal Pathway for FQHCs. Primary source: Sidley Austin LLP. Retrieved April 28, 2026, from https://www.fqhctalent.com/intel/ninth-circuit-fca-340b-overcharges-march-2026
More in Risk & Compliance
Jul 5
Section 1557 Language Access Annual Notice Year 1 Anniversary — July 5, 2026 Compliance Window
May 11
URGENT: HHS Section 504 WCAG 2.1 AA Digital Accessibility Deadline Hits FQHCs May 11, 2026 — 3 Weeks Away
Apr 27
HRSA 340B Rebate Model ICR Burden Comment Window Closes April 27 — Second Window for FQHCs After April 20 Main Deadline
Apr 22
Section 504 / WCAG 2.1AA 'Red Alert' — Enforcement Interpretation May Be Contested in Final Weeks Before May 11